Navigate the fast-moving cannabis sector with 420 Investor, a premium service that sends real-time alerts and explanations of the news below and much more.

Summary

• The Senate passed a cannabis bill, while the House prepares to vote on the MORE Act next week.
• 420 Investor model portfolios have returned 7.3% to 14.3% year-to-date, while the Global Cannabis Stock Index has lost 9.2%

Review

New Jersey delayed the start of adult-use sales, citing insufficient supply, as it approved 68 new conditional licenses for cultivation and production. The House of Representatives will be voting again on MORE Act, which it previously approved in late 2020, next week. The MORE Act is would legalize cannabis. The Senate unanimously approved the Cannabidiol and Marihuana Research Expansion Act, which would streamline the research process in order to help get FDA-approved cannabis-derived medications to market.

During the week, I shared these insights with subscribers at 420 Investor:

• Cannabis Sub-Sector Review – 03/18/22
• Model Portfolio Composition 03/18/22
• Previews of Q4 Financial Reports for Charlotte’s Web and Cresco Labs
• Another Look at MariMed

Here are some of this week’s highlights for 420 Investor Focus List names:

• AAWH began distributing Wynk THC and CBD infused seltzers in Michigan. It also will introduce partner brand Miss Grass into Massachusetts and Illinois.
• AYRWF introduced Entourage vape pens in Florida.
• CCHWF reported Q4 revenue of $139 million and guided for 2022 revenue to be $625-675 million with adjusted EBITDA of $120-135 million.
• CGC announced positive results from a 40-patient trial regarding CBD efficacy for menstrual health.
• CRLBF opened its 16th Florida dispensary. It agreed to acquire Columbia Care in an all-stock deal. The company reported Q4 revenue of $218 million with adjusted EBITDA of $57 million.
• CRON replaced its CEO with Chairman Mike Gorenstein and gave him 3 million restricted shares that vest in three years.
• CWBHF signed a UK distribution agreement with Savage Cabbage. Q4 revenue grew 5% sequentially but fell 8% from a year ago to $24.8 million.
• OGI reported new product launches, continued market share gains and progress towards a successful integration of its recent acquisition of Laurentian.
• TLRY launched a new wellness product under the Solei brand to promote sleep.
• TRSSF investor JW Asset Management increased its stake and now controls 44% of the company’s voting power on a partially diluted basis.

Market Performance

The Global Cannabis Stock Index extended the rally to two weeks, increasing 9.9% to 29.82:

The index, which lost 26% in 2021 following a 5.2% gain in 2020, is down 9.2% in 2022. It currently includes 38 stocks and ended 2021 at 32.85:

Model Portfolios

420 Investor offers three model portfolios for subscribers, including two that are long-term focused and fully invested with a goal of beating the Global Cannabis Stock Index, 420 Opportunity and 420 Quality. 420 Opportunity ended the week valued at $99,392, up 7.9%. The model portfolio, down 13.8% in 2021 after a 35.6% gain in 2020, is up 1.5% in 2022 and has increased 98.8% since April 2014 despite the large loss in the index since then. 420 Quality ended the week at $135,539, up 7.2% for the week. It is up 7.2 in 2022 and was down 21.8% in 2021 after gaining 42.8% in 2020. The model was launched in March 2017 targeting long-term investors seeking to invest in leading cannabis stocks with low portfolio turnover and has gained 171.1% since inception compared to the 63.1% decline in the index since then. Flying High, which is focused on swing trades, ended the week valued at $336,239, up 13.2%. The model portfolio gained 16.6% in 2021 and 52.7% in 2020 and is up 14.3% in 2022. The return since inception in late 2013 has been 3262%.

Outlook

The cannabis sector has continued to evolve through several ups and downs over the past few years. 2021 began by extending on massive gains in Q4 but hit a wall in mid-February, sliding the balance of the year after the market had gotten ahead of itself. Disappointment over the slow pace of federal reforms or the move towards legalization was a factor, but decreasing growth in cannabis sales, regulatory delays in several states and the implosion of the wholesale flower market in California played roles as well. In Canada, while the market has continued to grow, the evolution to derivative products has been slow. Additionally, the largest LPs have lost market share and have been unable to scale thus far.

The bull market that began in March 2020 after the pandemic and the capital crunch that followed the vaping crisis in 2019 appears to be intact for the American cannabis operators, which continue to trade sharply higher than where they traded in the summer of 2020 despite large declines from the peak in February. Looking forward, the outlook appears strong, with the leading companies moving to positive operating cash flow and having increasing access to non-dilutive capital, including debt, mortgages and sale-leasebacks. Several states will be moving from medical-only to adult-use, including New Jersey, New Mexico, Vermont and Connecticut in 2022, New York in 2023 and Virginia in 2024. Several other states could move to legalize for adult-use as well, including Delaware, Florida, Maryland, Minnesota, New Hampshire, Pennsylvania and Rhode Island. Several states are expanding programs as well, with additional dispensaries ahead for Illinois. Medical-only state Minnesota will be adding flower and edibles in 2022, and Ohio is expanding its program as well. Increasing competition within certain state markets that is weighing on profitability will likely remain a challenge. Further, while many see federal legalization as a positive, this remains a potential risk-factor in my view.

While the stocks of American cannabis companies continue to be held by mainly retail investors, 2021 saw an increase in institutional investment. Another big development has been the growth in AdvisorShares Pure US Cannabis ETF (MSOS), which has broadened the access to cannabis companies for investors that don’t trade OTC stocks. Additionally, a number of ancillary companies have gone public and trade on higher exchanges, offering institutional investors a way to invest in the industry. We have seen several investments into American cannabis companies, mainly by Canadian LPs, but, looking ahead, strategic investment through creative financial structures will likely extend to CPG companies in 2022.

At the federal level, the FDA (or Congress) could provide clarity on CBD regulation. With respect to THC, both Democrats (Cannabis Administration and Opportunity Act) and Republicans (States Reform Act) are advancing legislation to legalize cannabis. While this is going to be a long process in my view due to the complexity (varying state regulations, role of FDA, social equity, taxation), this is very different from what the developing cannabis sector faced just a few years ago: potential crackdowns against state legalization. I remain hopeful that Congress can advance small reforms, including expanded research and SAFE Banking. An enhanced financial reform that explicitly permitted companies operating in state-legal cannabis to trade on higher exchanges would be extremely positive.

Beyond America, cannabis legalization continues to proliferate. While Canada remains the largest federally legal cannabis market, many other countries have medical programs, including Argentina, Chile, Colombia, Ecuador, Peru and Uruguay (fully legal) in South America. Mexico has legalized for possession but doesn’t yet have a regulated program, and it could legalize for adult-use as well. Australia’s medical program was slow to start but has gained traction. New Zealand has a medical program as well. In Africa, several countries have legalized medical cannabis. Europe, of course, has seen widespread adoption of medical cannabis. Germany has been slow to develop but could move to legalize for adult-use. Other markets where there is medical cannabis include Denmark, Greece, Italy, Netherlands, Poland, and Portugal. The UK and Israel have medical cannabis, and Israel could move to legalize for adult-use. Of course, let’s not forget Jamaica!

Here are some of the most interesting stories we published on New Cannabis Ventures this week:

Agrify Q4 Revenue Increases 60% Sequentially to $25.3 Million

Aurora Cannabis to Acquire TerraFarma for $38 Million Before Earnouts

Charlotte’s Web Q4 Revenue Increases 5% Sequentially to $24.8 Million

Columbia Care Q4 Revenue Increases 5% to $139 Million

Cresco Labs Q4 Revenue Increases 1% Sequentially to $218 Million

Cresco Labs to Acquire Columbia Care

Exclusive: Gold Flora Ramps Up Vertically Integrated Footprint in California with Retail M&A

Jushi Q4 Revenue Increases 22% Sequentially to $65.9 Million

Nova Cannabis Q4 Revenue Increases 23% Sequentially to C$47.6 Million

Exclusive: Trulieve Has a Stake in This Profitable California Cannabis Company Generating $100 Million Revenue

Resources:

• Stay on top of all of the NCV news on publicly-traded stocks
• Track cannabis stocks with the Global Cannabis Stock Index
• Follow Canadian Producers with the Canadian Cannabis LP Index
• Monitor the American Cannabis Operator Index
• Stay on top of the Ancillary Cannabis Index
• Access free Canadian cannabis investor resources
• Learn about our featured companies
• Check out our "Revenue Tracker"
• Discover upcoming new issues and IPOs
• Stay on top of upcoming earnings calls
• Subscribe to the free Weekly Newsletter
• Follow all the NCV news real-time, by liking the Facebook page
• Get the NCV App (Apple)
• Get the NCV App (Google Play)
• Find a job with a leading cannabis company
• Read my articles on the Forbes Contributor site
• Read my articles on Leafly
• Subscribe to the 420 Investor Monthly Newsletter ($199 year)
• Become a 420 Investor VIP Member ($599 year)